Key result
Eprosartan 600 mg daily reduces BP in mild to severe hypertension with adverse events matching placebo.
Why the study?
Does eprosartan reduce blood pressure in patients with mild to severe hypertension?
Does eprosartan reduce blood pressure in patients with mild to severe hypertension?
Eprosartan is an effective and well-tolerated angiotensin II receptor antagonist for the treatment of mild to severe hypertension.
Answers are grounded in this paper and cite their sources.
May support eprosartan in hypertension; leaves open comparative RCTs versus other ARBs.
Eprosartan is a new, structurally distinct, nonbiphenyl, nontetrazole, nonpeptide, orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor. In placebo-controlled trials, it led to a dose-related antihypertensive response, clinically significant reductions in blood pressure and full 24-hour blood pressure control with once/day administration of 600 mg. Eprosartan provides clinically significant reductions in blood pressure in patients with mild to severe hypertension regardless of age, gender, and race. The antihypertensive effect of eprosartan is comparable with those of other antihypertensive agents. Whereas a relationship exists between dosage and antihypertensive effect, there is no such relationship between dosage and adverse events, the frequency of which is comparable with that with placebo.
No takes yet. Share an insight, caveat, or question.
Michael A. Weber (1999) conducted a review in mild to severe hypertension. Eprosartan vs. placebo was evaluated on blood pressure reduction. Eprosartan 600 mg once daily provided clinically significant reductions in blood pressure in patients with mild to severe hypertension, with an adverse event frequency comparable to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: